Radiopharmaceutical Theranostics Market Report Scope & Overview:

Radiopharmaceutical Theranostics Market was valued at USD 2.42 billion in 2025 and is expected to reach USD 6.93 billion by 2035, growing at a CAGR 11.14% of from 2026-2035.

The Radiopharmaceutical Theranostics Market is rapidly evolving, driven by the rising demand for precision oncology and targeted radioligand therapies. It focuses on integrating diagnostic and therapeutic capabilities to improve treatment efficacy, patient outcomes, and personalized care. Advances in isotope production, clinical research, and regulatory approvals are accelerating the adoption of novel theranostic solutions across healthcare systems globally.

Over 68% of global nuclear medicine centers have adopted theranostics, highlighting rapid oncology-focused growth worldwide.

Radiopharmaceutical Theranostics Market Size and Forecast

• Market Size in 2025: USD 2.42 Billion

• Market Size by 2035: USD 6.93 Billion

• CAGR: 11.14%

• Base Year: 2025

• Forecast Period: 2026-2035

• Historical Data: 2022-2024

Key Trends in the Radiopharmaceutical Theranostics Market

• Lu-177 and alpha-emitter therapies are increasingly adopted for targeted cancer treatment.

• Theranostics is integrated with precision oncology for personalized diagnosis and therapy.

• Hospitals and specialty cancer centers are expanding dedicated theranostic facilities.

• Asia-Pacific is growing rapidly due to increased PET/CT installations and local isotope production.

• Strategic partnerships are accelerating clinical trials and global adoption of theranostic treatments.

U.S. Radiopharmaceutical Theranostics Market Insights:

The U.S. Radiopharmaceutical Theranostics Market is projected to grow from USD 0.89 Billion in 2025 to USD 1.83 Billion by 2035, at a CAGR of 5.80%. Growth is driven by rising cancer prevalence, increased adoption of Lu-177 therapies, strong healthcare infrastructure, favorable FDA approvals, and expanding precision oncology and nuclear medicine programs.

Radiopharmaceutical Theranostics Market Growth Drivers:

• Rising Adoption of Precision Oncology and Targeted Radioligand Therapies

The increasing prevalence of cancers such as prostate cancer and neuroendocrine tumors is driving demand for precision oncology solutions. Theranostic radiopharmaceuticals, including Lu-177 and Ga-68–based agents, enable personalized diagnosis and treatment monitoring, improving patient outcomes. Adoption is supported by growing clinical evidence, favorable regulatory approvals, and rising awareness among oncologists and nuclear medicine centers worldwide.

Radiopharmaceutical Theranostics Market Restraints:

• High Production and Regulatory Complexity of Radiopharmaceuticals

The complex manufacturing processes, short half-life of isotopes, and stringent regulatory requirements limit large-scale production and distribution. Specialized facilities, cold-chain logistics, and trained personnel are required, increasing operational costs and restricting rapid market penetration, particularly in emerging regions with less developed nuclear medicine infrastructure.

Radiopharmaceutical Theranostics Market Opportunities:

• Expansion of Radiopharmaceutical Pipelines and Regional Infrastructure

Companies are investing in new radioligand therapies, including alpha- and beta-emitting isotopes, and establishing local production facilities in high-demand regions. Expanding PET/CT and nuclear medicine infrastructure in Asia-Pacific, Latin America, and the Middle East improves patient access. Strategic partnerships with hospitals, specialty cancer centers, and research institutions are accelerating clinical adoption and creating significant growth potential for the market.

Radiopharmaceutical Theranostics Market Segment:

• By Product Type: In 2025, Theranostic Pairs dominated with 62% share; Therapeutic Radiopharmaceuticals fastest growing segment during 2026-2035

• By Radioisotope: In 2025, Lutetium-177 (Lu-177) dominated with 56% share; Actinium-225 fastest growing segment during 2026-2035

• By Application: In 2025, Oncology dominated with 82% share; Neurology fastest growing segment during 2026-2035

• By End User: In 2025 Hospitals dominated with 59% share; Specialty Cancer Centers fastest growing segment during 2026-2035

Radiopharmaceutical Theranostics Market Segment Analysis:

By Product Type: Theranostic Pairs Dominate, Therapeutic Radiopharmaceuticals Fastest-Growing

Theranostic pairs dominate the product type segment due to their integrated diagnostic–therapeutic approach, enabling patient-specific treatment planning and real-time therapy monitoring. The clinical success of paired agents such as Ga-68/Lu-177 labeled compounds in prostate cancer and neuroendocrine tumors has driven widespread adoption. Their ability to improve treatment efficacy, reduce unnecessary radiation exposure, and align with precision oncology workflows strongly supports their leading market position.

Therapeutic radiopharmaceuticals are the fastest-growing product type, supported by rapid pipeline expansion of beta- and alpha-emitting agents. Increasing regulatory approvals, growing investment in radioligand therapy, and rising demand for targeted cancer treatments are accelerating adoption across advanced oncology care settings.

By Radioisotope: Lutetium-177 Dominates, Actinium-225 Fastest-Growing

Lutetium-177 dominates the radioisotope segment owing to its favorable half-life, optimal beta-emission profile, and well-established clinical safety. Its proven effectiveness in treating prostate cancer and neuroendocrine tumors, along with scalable production and global supply chain maturity, has made Lu-177 the preferred isotope in commercial theranostic therapies.

Actinium-225 is the fastest-growing radioisotope, driven by its high-energy alpha emissions that deliver potent tumor-killing capability with minimal damage to surrounding tissue. Strong clinical trial momentum, especially in treatment-resistant cancers, and increasing investment in isotope production technologies are accelerating its future adoption.

By Application: Oncology Dominates, Neurology Fastest-Growing

Oncology dominates the application segment due to the high global cancer burden and the strong clinical efficacy of theranostic radiopharmaceuticals in prostate cancer and neuroendocrine tumors. Targeted radioligand therapies enable precise tumor localization and personalized dosing, significantly improving patient outcomes and driving sustained demand in oncology-focused nuclear medicine.

Neurology is the fastest-growing application segment, supported by rising research into neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Increasing use of PET-based molecular imaging for early diagnosis and therapy monitoring is expanding the role of theranostics in neurological care.

By End User: Hospitals Dominate, Specialty Cancer Centers Fastest-Growing

Hospitals dominate the end-user segment due to their comprehensive nuclear medicine infrastructure, access to multidisciplinary oncology teams, and ability to manage radiopharmaceutical handling and regulatory compliance. High patient volumes and reimbursement availability further strengthen hospital adoption of theranostic procedures.

Specialty cancer centers represent the fastest-growing end-user segment, driven by focused oncology care models, increasing installation of dedicated theranostic suites, and rising demand for personalized cancer treatment pathways. Their streamlined workflows and expertise in advanced therapies are accelerating market growth.

Radiopharmaceutical Theranostics Market - Regional Analysis

North Radiopharmaceutical Theranostics Market Insights:

North America dominates the global radiopharmaceutical theranostics market, accounting for 42.30% of total market share in 2025. The region’s leadership is driven by early regulatory approvals of theranostic agents, a well-established nuclear medicine infrastructure, strong reimbursement frameworks, and high adoption of Lu-177–based radioligand therapies for oncology. The presence of major industry players, advanced isotope production facilities, and a large patient pool for prostate cancer and neuroendocrine tumors further reinforces North America’s dominant position in the global market.

Europe Radiopharmaceutical Theranostics Market Insights:

Europe represents a mature and strategically important region in the radiopharmaceutical theranostics market, supported by strong clinical research capabilities, established nuclear medicine practices, and widespread adoption of precision oncology. The region benefits from collaborative healthcare systems, early integration of theranostic protocols in oncology centers, and active participation in clinical trials for novel radioligand therapies. Strong regulatory oversight, increasing cross-border research collaborations, and the presence of leading radiopharmaceutical manufacturers and isotope suppliers continue to strengthen Europe’s role in advancing theranostic innovation and clinical adoption.

Asia-Pacific Radiopharmaceutical Theranostics Market Insights:

Asia-Pacific is the fastest-growing region in the global radiopharmaceutical theranostics market, registering a projected CAGR of approximately 19.1% during 2026–2035. Rapid growth is driven by rising cancer prevalence, expanding nuclear medicine infrastructure, increasing PET/CT installations, and strong government investments in healthcare modernization across China, India, Japan, and South Korea. Growing awareness of precision oncology, improving access to radioligand therapies, and local radioisotope production initiatives are further accelerating market expansion across the region.

Latin America Radiopharmaceutical Theranostics Market Insights:

Latin America is an emerging market for radiopharmaceutical theranostics, driven by improving healthcare infrastructure, growing oncology patient populations, and rising adoption of nuclear medicine technologies. Increasing investments in PET/CT imaging, expansion of public and private cancer centers, and greater awareness of precision oncology are supporting gradual uptake. Regional collaborations and technology transfers are enhancing access to advanced theranostic treatments.

Middle East & Africa Radiopharmaceutical Theranostics Market Insights:

The Middle East & Africa region is gradually adopting radiopharmaceutical theranostics, supported by expanding healthcare infrastructure, rising cancer awareness, and government initiatives to modernize oncology care. Investment in nuclear medicine facilities, partnerships with global radiopharmaceutical companies, and training of specialized medical professionals are facilitating market growth. Focused efforts on early diagnosis and targeted therapies are driving the region’s slow but steady adoption of theranostic solutions.

Radiopharmaceutical Theranostics Market Competitive Landscape:

Novartis AG, headquartered in Basel, Switzerland, is a global leader in the radiopharmaceutical theranostics market through its Advanced Accelerator Applications (AAA) division. The company specializes in targeted radioligand therapies for oncology, particularly prostate cancer and neuroendocrine tumors, leveraging integrated diagnostic–therapeutic platforms to enable precision oncology. Novartis focuses on Lu-177–based therapies supported by robust global manufacturing, isotope supply capabilities, and strong regulatory execution across major healthcare markets.

• In March 2025: Novartis expanded global production capacity for Lu-177 radioligand therapies by commissioning new radiopharmaceutical manufacturing lines, strengthening supply reliability and supporting rising demand for PSMA-targeted theranostic treatments.

Bayer AG, headquartered in Leverkusen, Germany, is a prominent player in the radiopharmaceutical theranostics market with a strong focus on oncology innovation and targeted alpha and beta radiotherapies. The company leverages its pharmaceutical expertise, strategic partnerships, and research-driven pipeline to advance next-generation radiopharmaceutical treatments, particularly for difficult-to-treat cancers. Bayer emphasizes clinical development, scalable manufacturing, and integration of radiopharmaceuticals into established oncology care pathways.

• In February 2025: Bayer advanced its radiopharmaceutical oncology pipeline by expanding clinical trials for targeted radioligand therapies, reinforcing its strategic commitment to precision cancer treatment and next-generation theranostic solutions.

Radiopharmaceutical Theranostics Market Key Players

• Novartis AG

• Bayer AG

• GE HealthCare

• Bracco Imaging S.p.A.

• Curium Pharma

• Lantheus Holdings, Inc.

• Telix Pharmaceuticals Limited

• Eckert & Ziegler

• Cardinal Health, Inc.

• Nordion (Sotera Health Company)

• Isotopen Technologien München (ITM)

• Blue Earth Diagnostics

• Theragnostics Ltd.

• NorthStar Medical Radioisotopes

• POINT Biopharma Global Inc.

• RadioMedix Inc.

• Fusion Pharmaceuticals

• BASF SE (radioisotope supply & materials support)

• IBA Radiopharma Solutions

• Siemens Healthineers